LOGIN  |  REGISTER
Surmodics

Boston Scientific (NYSE: BSX) Stock Quote

Last Trade: US$68.07 -0.77 -1.12
Volume: 4,690,980
5-Day Change: 0.47%
YTD Change: 17.75%
Market Cap: US$100.060B

Latest News From Boston Scientific

MARLBOROUGH, Mass. , April 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation (PFA) Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation (AF). The FARAVIEW technology and the FARAWAVE Nav catheter expand the capabilities of... Read More
MARLBOROUGH, Mass. , April 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2024 , on Wednesday, April 24, 2024 , at 8:00 a.m. ET . The call will be hosted by Mike Mahoney , chairman and chief executive officer, and Dan Brennan , executive vice president and chief financial officer. The... Read More
First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence MARLBOROUGH, Mass. , March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR)... Read More
MARLBOROUGH, Mass. , Feb. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) (the "Company") today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has completed a public offering of €750,000,000 aggregate principal amount of 3.375% notes due 2029 and €1,250,000,000 aggregate principal amount of 3.500% notes due 2032 (collectively, the "Notes"). The Notes are fully and... Read More
MARLBOROUGH, Mass. , Feb. 22, 2024 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has priced a public offering of €750,000,000 aggregate principal amount of 3.375% notes due 2029 and €1,250,000,000 aggregate principal amount of 3.500% notes due 2032 (collectively, the "Notes"). The Notes will be fully... Read More
MARLBOROUGH, Mass. , Feb. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 44 th Annual Health Care Conference on Wednesday, March 6, 2024 . Mike Mahoney , chairman and chief executive officer, will participate in a 30-minute question-and-answer session with the host analyst at approximately 9:10 a.m. ET . A live webcast of the session will be available on the Investor... Read More
MARLBOROUGH, Mass. , Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational 1 basis and 13.6 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504... Read More
HealthStocksHub
Strong clinical evidence base, largest volume of real-world use reinforce safety, efficacy and efficiency advantages of the system MARLBOROUGH, Mass. , Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed... Read More
Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction MARLBOROUGH, Mass. , Jan. 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technology company primarily focused on the development and commercialization of differentiated... Read More
MARLBOROUGH, Mass. , Jan. 5, 2024 /PRNewswire/ - - Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2023 , on Wednesday, January 31, 2024 , at 8:00 a.m. ET . The call will be hosted by Mike Mahoney , chairman and chief executive officer, and Dan Brennan , executive vice president and chief financial... Read More
MARLBOROUGH, Mass. , Dec. 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System* as a first-line treatment for persistent atrial fibrillation (AF), the only trial to study the use of PFA as frontline therapy in patients with this form of AF. Outcomes of ablation with the... Read More
Recent healthcare plan coverage of Intracept ® system expands access to vertebrogenic pain treatment for tens of millions of patients MARLBOROUGH, Mass. , Nov. 17, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only U.S. Food and Drug Administration-cleared Intracept ® Intraosseous Nerve Ablation System, a... Read More
MARLBOROUGH, Mass. , Nov. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2023 Healthcare Conference on Tuesday, November 14, 2023 . Dan Brennan , executive vice president and chief financial officer, and Lauren Tengler , vice president, Investor Relations, will participate in a 30-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET . A live... Read More
MARLBOROUGH, Mass. , Oct. 26, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational 1 basis and 10.2 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $505... Read More
HealthStocksHub
Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB MARLBOROUGH, Mass. and SAN FRANCISCO , Oct. 25, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal AGENT IDE clinical trial of the... Read More
Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass. , Oct. 24, 2023 /PRNewswire/ -- Data from the REAL-PE study was presented today at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, demonstrating that patients treated for pulmonary embolism... Read More
MARLBOROUGH, Mass. , Oct. 2, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023 , on Thursday, October 26, 2023 , at 8:00 a.m. EDT . The call will be hosted by Mike Mahoney , chairman and chief executive officer, and Dan Brennan , executive vice president and chief financial... Read More
Acquisition intended to expand neuromodulation portfolio to provide more treatment options for people living with chronic low back pain MARLBOROUGH, Mass. , Sept. 19, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept ®... Read More
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass. , Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration approval for the latest-generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device. Designed to further advance the procedural... Read More
MARLBOROUGH, Mass. , Sept. 5, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 20, 2023 , between 8:30 a.m. and 1:00 p.m. ET . "Our results in the first half of 2023 exceeded our expectations and demonstrated the strength of our category leadership strategy, commitment to... Read More
Noninferiority established through high treatment success, low adverse event rates Findings presented at ESC Congress 2023 and simultaneously published in The New England Journal of Medicine MARLBOROUGH, Mass. and AMSTERDAM , Aug. 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE™ Pulsed Field Ablation (PFA)... Read More
First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems MARLBOROUGH, Mass. , Aug. 8, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the POLARx™ Cryoablation System. The new system, which is indicated for the treatment of patients with paroxysmal... Read More
MARLBOROUGH, Mass. , July 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported basis, 12.0 percent on an operational 1 basis and 11.6 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $261... Read More
MARLBOROUGH, Mass. , June 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2023 on Thursday, July 27, 2023 at 7:30 a.m. EDT . The call will be hosted by Mike Mahoney , chairman and chief executive officer, and Dan Brennan , executive vice president and chief financial officer. The... Read More
MARLBOROUGH, Mass. , June 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Jessica L. Mega and Susan E. Morano to its board of directors, each effective immediately. Dr. Mega is the co-founder of Verily Life Sciences LLC, a subsidiary of Alphabet Inc. focused on life sciences and healthcare, and was the company's chief medical and scientific officer from 2015 to January... Read More
MARLBOROUGH, Mass. , May 30, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today that its Series A 5.50% Mandatory Convertible Preferred Stock (the preferred stock) will automatically convert into shares of the company's common stock on June 1, 2023 . As previously disclosed, holders of record at the close of business on May 15, 2023 will separately receive a final quarterly cash dividend of $1.375... Read More
Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the FARAPULSE™ Pulsed Field Ablation System* Results from global trial of the POLARx™ Cryoablation System* meet safety and effectiveness endpoints MARLBOROUGH, Mass. , May 20, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company's key electrophysiology and cardiac... Read More
MARLBOROUGH, Mass. , May 15, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 39 th Annual Strategic Decisions Conference on Wednesday, May 31, 2023 . Mike Mahoney , chairman and chief executive officer, will participate in a 50-minute question-and-answer session with the host analyst at approximately 8:00 a.m. EDT . A live webcast of the session will be available on the Investor... Read More
MARLBOROUGH, Mass. , April 26, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational 1 basis and 14.0 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $300... Read More
MARLBOROUGH, Mass. , April 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2023 on Wednesday, April 26, 2023 at 8:00 a.m. EDT . The call will be hosted by Mike Mahoney , chairman and chief executive officer, and Dan Brennan , executive vice president and chief financial officer. The... Read More
MARLBOROUGH, Mass. , Jan. 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 in San Francisco, California . Mike Mahoney , chairman and chief executive officer, will present at approximately 8:15 a.m. PST / 11:15 a.m. EST . Mahoney will be joined by Dan Brennan , executive vice president and chief financial... Read More
MARLBOROUGH, Mass. , Dec. 11, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and Acotec Scientific Holdings Limited ("Acotec" and 6669.HK) announced today that Boston Scientific will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares of Acotec , a Chinese medical technology company that offers solutions designed for a variety of interventional procedures. The proposed price is... Read More
Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures MARLBOROUGH, Mass. , Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc. (Nasdaq: APEN) for a cash price of $10 per share, reflecting an enterprise value of approximately $615 million . 1 The... Read More
HealthStocksHub
MARLBOROUGH, Mass. , Nov. 27, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2 TM Aortic Valve System. The findings, which included a high procedural success rate of... Read More
Compass Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB